The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer. Verzenio (abemaciclib) is now licensed to treat adult patients with hormone ...
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis. Verzenio (abemaciclib) is a CDK4 and 6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback